Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Incyte Corporation
  6. Summary
    INCY   US45337C1027

INCYTE CORPORATION

(INCY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/10/2022 01/11/2022 01/12/2022 01/13/2022 01/14/2022 Date
74.66(c) 74.44(c) 73.62(c) 73.65(c) 74.88(c) Last
2 084 909 1 317 443 1 638 813 1 319 180 1 580 839 Volume
+2.01% -0.29% -1.10% +0.04% +1.67% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 2 927 M - -
Net income 2021 525 M - -
Net cash position 2021 2 043 M - -
P/E ratio 2021 31,9x
Yield 2021 -
Sales 2022 3 444 M - -
Net income 2022 680 M - -
Net cash position 2022 2 857 M - -
P/E ratio 2022 23,7x
Yield 2022 -
Capitalization 16 540 M 16 540 M -
EV / Sales 2021 4,95x
EV / Sales 2022 3,97x
Nbr of Employees 1 773
Free-Float -
More Financials
Company
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (77.6%); - royalties (14.7%); - income from research and cooperation agreements (7.7%). 
Read more
More about the company
Ratings of Incyte Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about INCYTE CORPORATION
01/14Incyte Names Thomas Tray as Chief Accounting Officer
MT
01/14INCYTE CORP : Change in Directors or Principal Officers (form 8-K)
AQ
01/14Incyte Corporation Announces Executive Changes, Effective March 11, 2022
CI
01/11INSIDER SELL : Incyte
MT
01/10MorphoSys Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guida..
AQ
01/06INSIDER SELL : Incyte
MT
01/06RBC Raises Price Target on Incyte to $78 From $76, Maintains Sector Perform Rating
MT
01/05InnoCare Pharma Says Unaware of Reasons for 'Unusual Fluctuations' in Share Price
MT
01/03Guggenheim Adjusts Price Target for Incyte to $104 From $118, Maintains Buy Rating
MT
2021INSIDER SELL : Incyte
MT
2021INCYTE CORPORATION(NASDAQGS : INCY) dropped from NASDAQ-100 Index
CI
2021Bristol Myers drug wins first U.S. approval for Graft versus Host Disease prevention
RE
2021INCYTE CORPORATION : Report
CO
2021Incyte Gets US FDA Priority Review for Ruxolitinib Cream to Treat Vitiligo
MT
2021Incyte Announces Acceptance and Priority Review of sNDA for Ruxolitinib Cream (Opzelura..
BU
More news
News in other languages on INCYTE CORPORATION
01/14Incyte Corporation annonce des changements au niveau de la direction, à compter du 11 m..
01/07Morphosys will mit Krebsmedikament zulegen - Aktie weiter unter Druck
01/06VENTE PAR DES INITIÉS : Incyte
2021Incyte meldet Annahme und prioritäre Prüfung des sNDA-Antrags für Ruxolitinib-Creme (Op..
2021Incyte annonce que sa demande d'indication supplémentaire (sNDA) pour la crème au ruxol..
More news
Analyst Recommendations on INCYTE CORPORATION
More recommendations
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | INCY | US45337C1027 | MarketScreener
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 74,88 $
Average target price 93,76 $
Spread / Average Target 25,2%
EPS Revisions
Managers and Directors
Herve Hoppenot Chairman, President & Chief Executive Officer
Christiana Stamoulis Chief Financial Officer & Executive Vice President
Steven H. Stein Chief Medical Officer & Executive Vice President
Dashyant Dhanak Chief Scientific Officer & Executive VP
Julian Charles Baker Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
INCYTE CORPORATION2.02%16 540
MODERNA, INC.-19.39%83 008
LONZA GROUP AG-15.15%52 584
IQVIA HOLDINGS INC.-12.33%47 252
SEAGEN INC.-11.33%25 068
ICON PUBLIC LIMITED COMPANY-13.98%21 684